Oxford Gene Therapy Research
June 15th, 2014 by admin
(release date: January 2014) The first clinical trial of a gene therapy for an inherited cause of progressive blindness called choroideremia has shown very promising initial results, surpassing the expectations of the researchers involved. Professor Robert MacLaren of the Nuffield Laboratory of Ophthalmology (part of the Nuffield Department of Clinical Neurosciences) led the development of the retinal gene therapy and this first clinical trial. Click here to read the rest of the Oxford Press Release
The Choroideremia Research Foundation provided critical early funding to Dr. Miguel Seabra, a key collaborator on this Gene Therapy trial, helping to pave the way for this exciting breakthrough.